OptimizeRx (OPRX) 10-Q 14 Nov 24 2024 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Sep. 30, 2024	Nov. 08, 2024
Document Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Transition Report	false
Entity Interactive Data Current	Yes
Amendment Flag	false
Document Period End Date	Sep. 30, 2024
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q3
Entity Information [Line Items]
Entity Registrant Name	OptimizeRx Corporation
Entity Central Index Key	0001448431
Entity File Number	001-38543
Entity Tax Identification Number	26-1265381
Entity Incorporation, State or Country Code	NV
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Shell Company	false
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Contact Personnel [Line Items]
Entity Address, Address Line One	260 Charles Street
Entity Address, Address Line Two	Suite 302
Entity Address, City or Town	Waltham
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02453
Entity Phone Fax Numbers [Line Items]
City Area Code	248
Local Phone Number	651-6568
Entity Listings [Line Items]
Title of 12(b) Security	Common Stock, par value $0.001
Trading Symbol	OPRX
Security Exchange Name	NASDAQ
Entity Common Stock, Shares Outstanding		18,420,906

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Current assets
Cash and cash equivalents	$ 16,126	$ 13,852
Accounts receivable, net of allowance for credit losses of $339 and $239 at September 30, 2024 and December 31, 2023, respectively	26,327	36,253
Taxes receivable	64	1,036
Prepaid expenses and other	4,389	3,190
Total current assets	46,906	54,331
Property and equipment, net	161	149
Other assets
Goodwill	70,869	78,357
Technology assets, net	8,383	9,013
Patent rights, net	5,685	6,185
Tradename and customer relationships, net	32,411	34,198
Operating lease right of use assets, net	422	573
Security deposits and other assets	362	568
Total other assets	118,132	128,894
TOTAL ASSETS	165,199	183,374
Current liabilities
Current portion of long-term debt	2,000	2,000
Accounts payable – trade	2,754	2,227
Accrued expenses	5,557	7,755
Revenue share payable	3,210	5,506
Current portion of lease liabilities	195	222
Deferred revenue	786	172
Total current liabilities	14,502	17,882
Non-current liabilities
Long-term debt, net	33,278	34,231
Lease liabilities, net of current portion	242	371
Deferred tax liabilities, net	2,712	4,337
Total liabilities	50,734	56,821
Commitments and contingencies (See note 12)
Stockholders’ equity
Preferred stock, $0.001 par value, 10,000,000 shares authorized, none issued and outstanding at September 30, 2024 or December 31, 2023
Common stock, $0.001 par value, 166,666,667 shares authorized, 20,069,432 and 19,899,679 shares issued at September 30, 2024 and December 31, 2023, respectively	20	20
Treasury stock, $0.001 par value, 1,741,397 shares held at September 30, 2024 and December 31, 2023	(2)	(2)
Additional paid-in-capital	198,737	190,793
Accumulated deficit	(84,290)	(64,258)
Total stockholders’ equity	114,465	126,553
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 165,199	$ 183,374

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]
Accounts receivable, net of allowance for credit losses (in Dollars)	$ 339	$ 239
Preferred stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	166,666,667	166,666,667
Common stock, shares issued	20,069,432	19,899,679
Treasury stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Treasury stock, shares held	1,741,397	1,741,397

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Income Statement [Abstract]
Net revenue	$ 21,309	$ 16,331	$ 59,811	$ 43,153
Cost of revenues, exclusive of depreciation and amortization presented separately below	7,862	6,531	22,456	18,094
Gross profit	13,447	9,800	37,355	25,059
Operating expenses
General and administrative expenses	13,425	12,886	43,971	39,162
Goodwill impairment	7,489		7,489
Depreciation and amortization	1,095	467	3,235	1,395
Total operating expenses	22,009	13,353	54,695	40,557
Loss from operations	(8,562)	(3,553)	(17,340)	(15,499)
Other income (expense)
Interest expense	(1,524)		(4,597)
Other income	38		113
Interest income	107	688	231	2,074
Total other income (expense), net	(1,379)	688	(4,253)	2,074
Loss before provision for income taxes	(9,941)	(2,865)	(21,593)	(13,424)
Benefit from income taxes	817		1,561
Net loss	$ (9,124)	$ (2,865)	$ (20,032)	$ (13,424)
Weighted average number of shares outstanding – basic (in Shares)	18,323,542	16,637,606	18,250,775	16,907,482
Weighted average number of shares outstanding – diluted (in Shares)	18,323,542	16,637,606	18,250,775	16,907,482
Loss per share – basic (in Dollars per share)	$ (0.5)	$ (0.17)	$ (1.1)	$ (0.79)
Loss per share – diluted (in Dollars per share)	$ (0.5)	$ (0.17)	$ (1.1)	$ (0.79)

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Stockholders’ Equity (Unaudited) - USD ($) $ in Thousands	Common Stock	Treasury Stock	Additional Paid in Capital	Accumulated Deficit	Total
Balance at Dec. 31, 2022	$ 18	$ (1)	$ 172,786	$ (46,692)	$ 126,111
Balance (in Shares) at Dec. 31, 2022	18,288,571	(1,214,398)
Options			1,467		1,467
Restricted stock			2,914		2,914
For options exercised (in Shares)	9,668
For options exercised			41		41
For restricted stock units vested			(170)		(170)
For restricted stock units vested (in Shares)	33,272
Net loss				(6,398)	(6,398)
Balance at Mar. 31, 2023	$ 18	$ (1)	177,036	(53,090)	123,964
Balance (in Shares) at Mar. 31, 2023	18,331,511	(1,214,398)
Balance at Dec. 31, 2022	$ 18	$ (1)	172,786	(46,692)	126,111
Balance (in Shares) at Dec. 31, 2022	18,288,571	(1,214,398)
Balance at Jun. 30, 2023	$ 18	$ (2)	173,050	(57,251)	115,815
Balance (in Shares) at Jun. 30, 2023	18,376,771	(1,741,397)
Balance at Dec. 31, 2022	$ 18	$ (1)	172,786	(46,692)	126,111
Balance (in Shares) at Dec. 31, 2022	18,288,571	(1,214,398)
Net loss					(13,424)
Balance at Sep. 30, 2023	$ 18	$ (2)	176,207	(60,117)	116,107
Balance (in Shares) at Sep. 30, 2023	18,386,920	(1,741,397)
Balance at Mar. 31, 2023	$ 18	$ (1)	177,036	(53,090)	123,964
Balance (in Shares) at Mar. 31, 2023	18,331,511	(1,214,398)
Options			1,655		1,655
Repurchase of common stock		$ (1)	(7,522)		(7,522)
Repurchase of common stock (in Shares)		(526,999)
Restricted stock			1,848		1,848
For options exercised (in Shares)	10,000
For options exercised			105		105
For restricted stock units vested			(73)		(73)
For restricted stock units vested (in Shares)	35,260
Net loss				(4,161)	(4,161)
Balance at Jun. 30, 2023	$ 18	$ (2)	173,050	(57,251)	115,815
Balance (in Shares) at Jun. 30, 2023	18,376,771	(1,741,397)
Options			1,598		1,598
Repurchase of common stock
Restricted stock			1,608		1,608
For options exercised
For restricted stock units vested			(49)		(49)
For restricted stock units vested (in Shares)	10,149
Net loss				(2,865)	(2,865)
Balance at Sep. 30, 2023	$ 18	$ (2)	176,207	(60,117)	116,107
Balance (in Shares) at Sep. 30, 2023	18,386,920	(1,741,397)
Balance at Dec. 31, 2023	$ 20	$ (2)	190,793	(64,258)	126,553
Balance (in Shares) at Dec. 31, 2023	19,899,679	(1,741,397)
Options			1,353		1,353
Restricted stock			1,671		1,671
For options exercised (in Shares)
For restricted stock units vested			(140)		(140)
For restricted stock units vested (in Shares)	22,200
Net loss				(6,900)	(6,900)
Balance at Mar. 31, 2024	$ 20	$ (2)	193,677	(71,158)	122,537
Balance (in Shares) at Mar. 31, 2024	19,921,879	(1,741,397)
Balance at Dec. 31, 2023	$ 20	$ (2)	190,793	(64,258)	126,553
Balance (in Shares) at Dec. 31, 2023	19,899,679	(1,741,397)
For options exercised (in Shares)
For restricted stock units vested (in Shares)	140,028
Balance at Jun. 30, 2024	$ 20	$ (2)	196,164	(75,166)	121,016
Balance (in Shares) at Jun. 30, 2024	20,061,907	(1,741,397)
Balance at Dec. 31, 2023	$ 20	$ (2)	190,793	(64,258)	126,553
Balance (in Shares) at Dec. 31, 2023	19,899,679	(1,741,397)
For options exercised (in Shares)
For restricted stock units vested (in Shares)	7,525
Net loss					(20,032)
Balance at Sep. 30, 2024	$ 20	$ (2)	198,737	(84,290)	114,465
Balance (in Shares) at Sep. 30, 2024	20,069,432	(1,741,397)
Balance at Mar. 31, 2024	$ 20	$ (2)	193,677	(71,158)	122,537
Balance (in Shares) at Mar. 31, 2024	19,921,879	(1,741,397)
Options			1,149		1,149
Restricted stock			1,753		1,753
For restricted stock units vested			(415)		(415)
For restricted stock units vested (in Shares)	140,028
Net loss				(4,008)	(4,008)
Balance at Jun. 30, 2024	$ 20	$ (2)	196,164	(75,166)	121,016
Balance (in Shares) at Jun. 30, 2024	20,061,907	(1,741,397)
Options			992		992
Repurchase of common stock
Restricted stock			1,612		1,612
For restricted stock units vested			(31)		(31)
For restricted stock units vested (in Shares)	7,525
Net loss				(9,124)	(9,124)
Balance at Sep. 30, 2024	$ 20	$ (2)	$ 198,737	$ (84,290)	$ 114,465
Balance (in Shares) at Sep. 30, 2024	20,069,432	(1,741,397)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
OPERATING ACTIVITIES:
Net loss	$ (20,032)	$ (13,424)
Adjustments to reconcile net loss to net cash provided by (used in) provided by operating activities:
Depreciation and amortization	3,235	1,395
Stock-based compensation	8,530	11,090
Goodwill impairment	7,489
Deferred income taxes	(1,625)
Bad debt expense	131	478
Amortization of debt issuance costs	547
Changes in:
Accounts receivable	9,795	838
Prepaid expenses and other assets	(1,200)	(728)
Accounts payable	527	(859)
Revenue share payable	(2,296)	(305)
Accrued expenses and other liabilities	(1,997)	509
Tax receivable	972
Deferred revenue	615	24
NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES	4,691	(982)
INVESTING ACTIVITIES:
Purchase of property and equipment	(95)	(82)
Purchases of held-to-maturity investments		(162,778)
Redemptions of held-to-maturity investments		165,089
Acquisition of intangible assets, including intellectual property rights		(4)
Capitalized software development costs	(235)	(1,561)
NET CASH (USED IN) PROVIDED BY INVESTING ACTIVITIES	(330)	664
FINANCING ACTIVITIES:
Cash paid for employee withholding taxes related to the vesting of restricted stock units	(587)	(293)
Proceeds from exercise of stock options		146
Repurchase of common stock		(7,522)
Loan origination costs		(300)
Repayment of long-term debt	(1,500)
NET CASH USED IN FINANCING ACTIVITIES	(2,087)	(7,969)
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	2,274	(8,287)
CASH AND CASH EQUIVALENTS - BEGINNING OF PERIOD	13,852	18,209
CASH AND CASH EQUIVALENTS - END OF PERIOD	16,126	9,923
SUPPLEMENTAL CASH FLOW INFORMATION:
Cash paid for interest	4,081
ROU assets obtained in exchange for lease obligations		158
Cash paid for income taxes

Nature of Business and Basis of

Nature of Business and Basis of Presentation	9 Months Ended
	Sep. 30, 2024
Nature of Business and Basis of Presentation [Abstract]
NATURE OF BUSINESS AND BASIS OF PRESENTATION	NOTE 1 – NATURE OF BUSINESS AND BASIS OF PRESENTATION The accompanying condensed consolidated financial statements include OptimizeRx Corporation and its wholly owned subsidiaries (collectively, the “Company”, “we”, “our”, or “us”). We are a digital health technology company enabling care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. Connecting over two million U.S. healthcare providers and millions of their patients through an intelligent technology platform embedded within a proprietary point-of-care network, as well as mass digital communications channels, OptimizeRx helps life sciences organizations engage and support their customers. The condensed consolidated financial statements for the three and nine months ended September 30, 2024 and 2023 have been prepared by us without audit pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). In the opinion of management, all adjustments necessary to present fairly our financial position at September 30, 2024, and our results of operations, changes in stockholders’ equity, and cash flows for the nine months ended September 30, 2024 and 2023, have been made. Those adjustments consist of normal and recurring adjustments. The condensed consolidated balance sheet as of December 31, 2023, has been derived from the audited consolidated condensed balance sheet as of that date. We operate a single reporting segment and, accordingly, use our consolidated net income as our measure of profit and loss and it is not presented separately here. Certain information and note disclosures, including a detailed discussion about the Company’s significant accounting policies, normally included in our annual consolidated financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted. These condensed consolidated financial statements should be read in conjunction with a reading of the consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, as filed with the SEC on April 15, 2024 (“Form 10-K”). The results of operations for the three and nine months ended September 30, 2024, are not necessarily indicative of the results to be expected for the full year. On October 24, 2023, the Company acquired 100% of the issued and outstanding preferred and common stock of Healthy Offers, Inc., a Nevada corporation d/b/a Medicx Health (“Medicx Health”) - See Part II, Item 8. Financials Statements and Supplementary Data; Note 3 - Acquisitions in our Form 10-K for additional information regarding this transaction. The following presents the pro forma consolidated statement of operations as if Medicx Health had been included in the consolidated results of the Company for the three and nine months ended September 30, 2023: Three Months Nine Months Pro-forma consolidated statement of operations September 30, Revenue $ 23,852 $ 67,291 Net loss (3,484 ) (18,141 ) These amounts have been calculated after applying the Company’s accounting policies, adjusting Medicx Health results to reflect the additional amortization that would have been charged assuming the fair value adjustments to intangible assets had been applied on January 1, 2023, interest expense associated with the term loan and elimination of interest income on short-term investments that were used to fund the acquisition, During the year ended December 31, 2023, the Company disposed of its non-core Access business - See Part II, Item 8. Financials Statements and Supplementary Data; Note 7 - Goodwill and Intangible Assets in our Form 10-K for additional information regarding this transaction. A pro forma statement of operations for the three and nine months ended September 30, 2024 is not presented for this transaction as the pro forma impacts were not material to the Company’s consolidated results. Revenue presented in the pro forma financial consolidated statement of operations data above includes $1,088 and $4,169, respectively related to the Access and other non-core solutions for which no revenue was recorded in the three and nine months ended September 30, 2024 (see also the discussion under Net Revenues in Results of Operations for the three and nine months ended September 30, 2024 in Part I, Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations). Change in Accounting Estimate In accordance with its policy, the Company periodically reviews the stand-alone selling prices of its performance obligations under Revenue from Contracts with Customers Fair Value of Financial Instruments Fair value is defined as the price that would be received upon the sale of an asset or paid upon the transfer of a liability in an orderly transaction between market participants at the measurement date and in the principal or most advantageous market for that asset or liability. The fair value should be calculated based on assumptions that market participants would use in pricing the asset or liability, not on assumptions specific to the entity. In addition, the fair value of liabilities should include consideration of non-performance risk including our own credit risk. In addition to defining fair value, the disclosure requirements around fair value establish a fair value hierarchy for valuation inputs, which is expanded. The hierarchy prioritizes the inputs into three levels based on the extent to which inputs used in measuring fair value are observable in the market. Each fair value measurement is reported in one of the three levels, which is determined by the lowest level input that is significant to the fair value measurement in its entirety. These levels are: Level 1 – Inputs are based upon unadjusted quoted prices for identical instruments traded in active markets. Level 2 – Inputs are based upon significant observable inputs other than quoted prices included in Level 1, such as quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 – Inputs are generally unobservable and typically reflect management’s estimates of assumptions that market participants would use in pricing the asset or liability. The fair values are therefore determined using model-based techniques that include option pricing models, discounted cash flow models, and similar techniques. The Company’s stock options and warrants are valued using Level 3 inputs. The Company’s carrying amounts of financial instruments, including cash and cash equivalents, accounts receivable, accounts payable, and other current liabilities, approximate their fair values due to their short maturities.

New Accounting Pronouncements

New Accounting Pronouncements	9 Months Ended
	Sep. 30, 2024
New Accounting Pronouncements [Abstract]
NEW ACCOUNTING PRONOUNCEMENTS	NOTE 2 – NEW ACCOUNTING PRONOUNCEMENTS In November 2023, the FASB issued ASU No. 2023-07 (“ASU 2023-07”), Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. ASU 2023-07 requires annual and interim disclosures that are expected to improve reportable segment disclosures, primarily through enhanced disclosures about significant segment expenses. The provisions of ASU 2023-07 are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. We are currently evaluating the impact of adopting ASU 2023-07. In December 2023, the FASB issued ASU No. 2023-09 (“ASU 2023-09”), Income Taxes (Topic 740): Improvements to Income Tax Disclosures. ASU 2023-09 addresses investor requests for more transparency about income tax information through improvements to income tax disclosures primarily related to the rate reconciliation and income taxes paid information. This update also includes certain other amendments to improve the effectiveness of income tax disclosures. The provisions of ASU 2023-09 are effective for annual periods beginning after December 15, 2024, with early adoption permitted. We are currently evaluating the impact of adopting ASU 2023-09.

Cash, Cash Equivalents and Shor

Cash, Cash Equivalents and Short-Term Investments	9 Months Ended
	Sep. 30, 2024
Cash, Cash Equivalents and Short-Term Investments [Abstract]
CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS	NOTE 3 – CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS Cash equivalents include items almost as liquid as cash comprised of investments in AAA rated money market funds that invest in first-tier only securities, which primarily include domestic commercial paper and securities issued or guaranteed by the U.S. government or its agencies. We account for marketable equity securities in accordance with ASC 321-10, “Investments - Equity Securities”, as the shares have a readily determinable fair value quoted on the national stock exchange and are classified within Level 1 of the fair value hierarchy. At September 30, 2024 and December 31, 2023, we have recorded $8.2 million and none, respectively, of money market funds at approximate fair value.

Capitalized Software Costs

Capitalized Software Costs	9 Months Ended
	Sep. 30, 2024
Capitalized Software Costs [Abstract]
CAPITALIZED SOFTWARE COSTS	NOTE 4 – CAPITALIZED SOFTWARE COSTS The Company capitalizes certain development costs incurred in connection with software development for internal-use software platforms used in operations and for providing services to our customers. Costs incurred in the preliminary stages of development are expensed as incurred. Once software has reached the development stage, internal and external costs, if direct, are capitalized until the software is substantially complete and ready for its intended use. Capitalization ceases upon completion of all substantial testing. The Company also capitalizes costs related to specific upgrades and enhancements when it is probable the expenditures will result in additional functionality. Capitalized internal use software development costs are included in intangible assets and are amortized on a straight-line basis over the estimated useful life of the software platforms and are included in depreciation and amortization within operating expenses in the consolidated statements of operations. Amortization of capitalized internal use software expense for the three and nine months ended September 30, 2024 and 2023 was $91 and $233 and $48 and $143, respectively. The Company accumulates capitalizable costs related to current projects in a construction in process (“CIP”) software account, the balance of which was $217 and $696 at September 30, 2024 and December 31, 2023, respectively.

Goodwill

Goodwill	9 Months Ended
	Sep. 30, 2024
Goodwill [Abstract]
GOODWILL	NOTE 5 – GOODWILL The Company has a single reporting segment. The goodwill is related to the acquisitions of Medicx Health in 2023, EvinceMed in 2022, RMDY Health, Inc. in 2019 and CareSpeak Communications in 2018. Goodwill is not amortizable for financial statement purposes. Goodwill is tested for impairment at a reporting segment level at least annually, as of December 31, or on an interim basis if an event occurs or circumstances change (a “Triggering Event”). During the third quarter of 2024, the Company experienced a Triggering Event due to a sustained decline in its stock price and overall market capitalization. Accordingly, the Company conducted a quantitative impairment test of its goodwill at September 30, 2024. The Company estimated the implied fair value of its goodwill using a combination of a market approach and income approach. At September 30, 2024 and December 31, 2023, the carrying amounts of goodwill were $70.9 million and $78.4 million, respectively. A noncash charge of $7.5 million, representing the amount by which the Company’s book value exceeds its estimated fair value, was recorded as a goodwill impairment in the three months ended September 30, 2024.

Long-Term Debt

Long-Term Debt	9 Months Ended
	Sep. 30, 2024
Long-Term Debt [Abstract]
LONG-TERM DEBT	NOTE 6 – LONG-TERM DEBT On October 11, 2023, in connection with the acquisition of Medicx Health, we entered into a financing agreement that provided for a $40 million term loan (the “Term Loan”). Long-term debt, net comprised the following at September 30, 2024 and December 31, 2023: September 30, December 31, Term Loan, due in 2027 $ 36,790 $ 38,290 Less: current portion (2,000 ) (2,000 ) Less: unamortized issuance costs (1,512 ) (2,059 ) Long-term debt, net $ 33,278 $ 34,231 As of September 30, 2024, the Term Loan bears interest at 14.0%, with an effective rate of 16.1%, including the impact of the amortization of debt issuance costs of $182 and $547 for the three and nine months ended September 30, 2024, respectively. On September 30, 2024, we entered into Amendment No. 2 to the financing agreement, which extended the test period for measurement of the leverage ratio and qualified cash measurements from September 30, 2024 to October 15, 2024. As of September 30, 2024, the Company was in full compliance with the financial covenants associated with the Term Loan. The Term Loan is repayable in quarterly installments, beginning December 31, 2023, equivalent to 1.25% or $0.5 million, of the original principal amount, with the outstanding unpaid principal and all accrued but unpaid interest due and payable on the earlier of (i) the fourth anniversary of the closing date of the Term Loan or (ii) the date on which the Term Loan is declared due and payable pursuant to the terms of the financing agreement. In addition, the Company is required to make a mandatory prepayment on March 31, of each year, commencing with 2025, equivalent to Excess Cash Flow multiplied by a percentage factor of 25%, if the leverage ratio is 3.60 to 1.00 or less, 50% if the leverage ratio is greater than 3.60 to 1 or less than or equal; to 4.10 to 1.00 and 75%, if the leverage ratio is greater than 4.10 to 1.00. Excess Cash Flow is defined in the financing agreement as Consolidated EBITDA for the previous fiscal year less scheduled principal and interest payments, capital expenditure, cash taxes and any cash expenses/gains added back to net income in the calculation of Consolidated EBITDA, adjusted for any increase/decrease in working capital during the fiscal year. Repayments of the Term Loan due under the terms of the financing agreement, including an estimate of the amount associated with the Excess Cash Flow calculation discussed above, for the remainder of the current and in each of the next three fiscal years are as follows: As of September 30, 2024 2024 (remainder) $ 500 2025 2,000 2026 2,000 2027 32,290 $ 36,790

Leases

Leases	9 Months Ended
	Sep. 30, 2024
Leases [Abstract]
LEASES	NOTE 7 – LEASES We had operating leases with terms greater than 12 months for office space in four multi-tenant facilities, which are recorded as Operating lease right-of-use assets and Operating lease liabilities. For the three and nine months ended September 30, 2024 and 2023, the Company’s lease costs consist of the following components, each of which is included in operating expenses within the Company’s condensed consolidated statements of operations: Three months ended Nine Months Ended 2024 2023 2024 2023 Operating lease cost $ 62 $ 11 $ 186 $ 61 Short-term lease cost 1 19 2 27 Total lease cost $ 63 $ 30 $ 188 $ 88 The table below presents the future minimum lease payments to be made under operating leases in each of the remainder of the current and next four fiscal years and thereafter: As of September 30, 2024 2024 (remainder) $ 67 2025 188 2026 114 2027 67 2028 46 Thereafter — Total 482 Less: discount 45 Total lease liabilities $ 437 The weighted average remaining lease term at September 30, 2024 for the operating leases is 2.7 years, and the weighted average discount rate used in calculating the operating leases assets and liabilities is 6.96%. Cash paid for amounts included in the measurement of lease liabilities was $168 and $53 for the nine months ended September 30, 2024 and 2023, respectively. For the nine months ended September 30, 2024 and 2023, payments on lease obligations were $193 and $60, respectively, and amortization on the right of use assets was $175 and $61, respectively.

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2024
Stockholders’ Equity [Abstract]
STOCKHOLDERS' EQUITY	NOTE 8 – STOCKHOLDERS’ EQUITY Preferred Stock The Company had 10,000,000 shares of preferred stock, $0.001 par value per share, authorized as of September 30, 2024. No Common Stock The Company had 166,666,667 shares of common stock, $0.001 par value per share, authorized as of September 30, 2024. There were 18,328,035 and 18,158,282 shares of common stock outstanding, net of shares held in treasury of 1,741,397 at September 30, 2024 and December 31, 2023, respectively. During each of the quarters ended March 31, 2024, June 30, 2024 and September 30, 2024, no During the quarters ended March 31, 2024, June 30, 2024 and September 30, 2024, 22,200, 140,028 and 7,525 shares of common stock, respectively, were issued in connection with the vesting of restricted stock units under our 2013 Incentive Plan and our 2021 Equity Incentive Plan. Some of the participants utilized a net withhold settlement method, in which shares were surrendered to cover payroll withholding taxes. Of the shares issued to participants during the nine months ended September 30, 2024, a total of 52,092 shares, valued at $585,571, were surrendered and subsequently cancelled. During the quarters ended March 31, 2023, June 30, 2023 and September 30, 2023, the Company issued 9,668, 10,000 and 0 shares of our common stock and received proceeds of $40, $105 and $0, respectively, in connection with the exercise of options under our 2013 Incentive Plan. During the quarters ended March 31, 2023, June 30, 2023 and September 30, 2023, the Company issued 33,272, 35,260 and 10,149 shares of common stock in connection with the vesting of restricted stock units under our 2013 Incentive Plan and our 2021 Equity Incentive Plan. 28,157 shares valued at $121 were surrendered in connection with the net withhold settlement method, and were subsequently cancelled. Treasury Stock During the quarter ended March 31, 2023, the Board authorized a share repurchase program, under which the Company could repurchase up to $15.0 million of its outstanding common stock. This stock repurchase authorization expired on March 12, 2024. There were no shares repurchased in 2024 prior to the expiration. During the three and nine months ended September 30, 2023, the Company repurchased none and 526,999 shares of common stock, respectively, under this program for a total of $7,522, including commissions paid on repurchases. These shares were recorded as treasury shares using the par value method.

Stock Based Compensation

Stock Based Compensation	9 Months Ended
	Sep. 30, 2024
Stock Based Compensation [Abstract]
STOCK BASED COMPENSATION	NOTE 9 – STOCK BASED COMPENSATION On June 5, 2024, at the 2024 Annual Meeting of Stockholders, the Company’s stockholders approved an amendment to the 2021 Equity Incentive Plan to increase the number of shares of common stock available for awards under the 2021 Equity Incentive Plan by 1,950,000 shares for a total of 4,450,000 shares. Stock Options The compensation expense related to options for the nine months ended September 30, 2024 and 2023 was $3,494 and $4,720, respectively. The fair value of these instruments was calculated using the Black-Scholes option pricing model. There is $4,115 of remaining expense related to unvested options to be recognized in the future over a weighted average period of 1.57 years. The total intrinsic value of outstanding options at September 30, 2024 was $8. During 2022, the Company granted certain performance-based stock options, the expense for which will be recorded over time once the achievement of the performance is deemed probable. There was $8 and $16 in expense related to these options recorded during the three and nine months ended September 30, 2024. Restricted Stock Units The Company recorded $5,036 and $6,370 in compensation expense related to restricted stock units for the nine months ended September 30, 2024 and 2023, respectively. A total of $6,793 remains to be recognized at September 30, 2024 over a weighted average period of 1.6 years. During 2022, the Company granted certain performance based restricted stock units, the expense for which will be recorded over time once the achievement of the performance is deemed probable. There was $8 and $16 in expense related to these restricted stock units recorded during the three and nine months ended September 30, 2024. The director’s compensation program calls for the grant of restricted stock units with a one year vesting period. There was $591 and $541 included in the compensation expense discussed above related to director’s compensation for the periods ended September 30, 2024 and 2023, respectively.

Revenues

Revenues	9 Months Ended
	Sep. 30, 2024
Revenues [Abstract]
REVENUES	NOTE 10 – REVENUES Under ASC Topic 606, we record revenue when earned, rather than when billed. From time to time, we may record revenue based on our revenue recognition policies in advance of being able to invoice the customer, or we may invoice the customer prior to being able to recognize the revenue. Included in accounts receivable are unbilled amounts of $6,002 and $3,288 at September 30, 2024, and December 31, 2023, respectively. Amounts billed in advance of revenue recognition are presented as deferred revenue on the condensed consolidated balance sheets. Revenues are primarily generated from content delivery activities in which the Company delivers financial, clinical, or brand messaging through a distribution network of ePrescribers and electronic health record technology providers (channel partners), directly to consumers, or from reselling services that complement the business. This content delivery for a customer is referred to as a program. Unless otherwise specified, revenue is recognized based on the selling price to customers. The Company’s contracts are generally less than one year and the primary performance obligation is delivery of messages, or content, but the contract may contain additional services. Additional services may include program design, which is the design of the content delivery program, set up, and reporting. We consider set up and reporting services to be complimentary to the primary performance obligation and recognized through performance of the delivery of content. We consider program design and related consulting services to be performance obligations separate from the delivery of messages. Revenue is recognized at the point in time when the work product is delivered to the customer. The net contract balance for contracts in progress at September 30, 2024 and December 31, 2023, was $23,191 and $2,021, respectively. The outstanding performance obligations are expected to be satisfied during the year ended December 31, 2024. In certain circumstances, the Company will offer sales rebates to customers based on spend volume. Rebates are contracted based on a quarterly or annual spend amount and on a volume threshold or tiered model. At the beginning of the year, the rebate percentage is estimated based on input from the sales team and analysis of prior year sales. Thereafter, the open contract balance for the customer is assessed quarterly to ensure the estimated rebate percentage being used for the rebate accrual remains reasonable. The estimated amount of variable consideration will be included in the transaction price only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. For the year ended 2023 and during the first nine months of 2024, there were two contracts with customers that included a rebate clause. As the content is distributed through the platform and network of channel partners (a transaction), these transactions are recorded, and transaction revenue is recognized over time as the distributions occur. Revenue for transactions can be realized based on a price per message, a price per redemption, as a flat fee occurring over a period of time, or upon completion of the program, depending on the client contract. The Company recognizes setup fees that are required for integrating client offerings and campaigns into the rule-based content delivery system and network over the life of the initial program, based either on time, or units delivered, depending upon which is most appropriate in the specific situation. Should a program be cancelled before completion, the balance of set up revenue is recognized at the time of cancellation, as set up fees are nonrefundable. Additionally, the Company also recognizes revenue for providing program performance reporting and maintenance. This reporting revenue is recognized over time as the messages are delivered. Program design, which is the design of the content delivery program, and related consulting services are recognized as services are performed. In some instances, we also resell messaging solutions that are available through channel partners that are complementary to the core business and client base. These partner specific solutions are frequently similar to our own solutions and revenue recognition for these programs is the same as described above. In instances where we sell solutions on a commission basis, net revenue is recognized based on the commission-based revenue split that we receive. In instances where we resell these messaging solutions and have all financial risk and significant operation input and risk, we record the revenue based on the gross amount sold and the amount paid to the channel partner as a cost of sales. The Company has several signed contracts with customers for the distribution of messaging, or other services, which include payment in advance. The payments are not recorded as revenue until the revenue is earned under our revenue recognition policy. Deferred revenue was $786 and $172 as of September 30, 2024 and December 31, 2023, respectively. The contracts are all short term in nature and all revenue is expected to be recognized within 12 months, or less. The following is a summary of activity for the deferred revenue account for the nine months ended September 30: 2024 2023 Balance January 1 $ 172 $ 164 Revenue recognized (3,228 ) (2,444 ) Amount collected 3,961 3,015 Balance March 31 $ 905 $ 735 Revenue recognized (1,853 ) (3,171 ) Amount collected 2,002 2,887 Balance June 30 $ 1,054 $ 451 Revenue recognized (2,721 ) (3,043 ) Amount collected 2,453 2,780 Balance September 30 $ 786 $ 188 Disaggregation of Revenue Consistent with ASC Topic 606, we have disaggregated our revenue by timing of revenue recognition. The majority of our revenue is recognized over time as solutions are provided. A small portion of our revenue related to program development, solution architect design, and other solutions is recognized at a point in time upon delivery to customers. A break down is set forth in the table below. Three Months Ended Nine Months Ended 2024 2023 2024 2023 Revenue recognized over time $ 20,441 $ 14,815 $ 54,189 $ 40,421 Revenue recognized at a point in time 868 1,516 5,622 2,732 Total Revenue $ 21,309 $ 16,331 $ 59,811 $ 43,153 Accounts receivable are reported at realizable value, net of allowances for credit losses, which is estimated and recorded in the period the related revenue is recorded. The Company does not seek collateral to secure its accounts receivable and amounts billed are generally due within a short period of time based on terms and conditions normal for our industry. The Company has a standardized approach to estimate and review the collectability of its receivables based on a number of factors, including the period they have been outstanding. Historical collection and payer reimbursement experience is an integral part of the estimation process related to allowances for credit losses. In addition, the Company regularly assesses the state of its billing operations in order to identify issues, which may impact the collectability of these receivables or reserve estimates. If current or expected future economic trends, events, or changes in circumstances indicate that specific receivable balances may be impaired, further consideration is given to the collectability of those balances and the allowance is adjusted accordingly. Past-due receivable balances are written off when the Company’s collection efforts have been exhausted. The following is a summary of changes in the allowance for credit losses for the nine months ended September 30,: 2024 2023 Balance at January 1, $ 239 $ 352 Bad debt expense 132 128 Write-offs — — Balance at March 31, $ 371 $ 480 Bad debt expense — 111 Write-offs — — Balance at June 30, $ 371 $ 591 Bad debt expense (1 ) 239 Write-offs 31 9 Balance at September 30, $ 339 $ 821 Related Party Transactions Related party transactions include transactions between the Company and its shareholders, management, or affiliates. The following transactions were in the normal course of operations and were measured and recorded at the exchange amount, which is the amount of consideration established and agreed to by the parties. During the three months ended September 30, 2024 we sold to Eversana and LifeMD resulting in $0.2 million recognized revenue where one or more of our executive officers or members of our Board of Directors were, during the periods presented, an executive officer or a board member. All of the related party transactions were made at current market rates.

Loss Per Share

Loss Per Share	9 Months Ended
	Sep. 30, 2024
Loss Per Share [Abstract]
LOSS PER SHARE	NOTE 11 – LOSS PER SHARE Basic earnings per share (“EPS”) is computed by dividing net income (loss) by the weighted average number of common shares outstanding during the period. The number of shares related to options and restricted stock units included in diluted EPS is based on the “Treasury Stock Method” prescribed in ASC 260-10, Earnings per Share The following table sets forth the computation of basic and diluted net loss per share. Three Months Ended Nine Months Ended 2024 2023 2024 2023 Numerator Net loss $ (9,124 ) $ (2,865 ) $ (20,032 ) $ (13,424 ) Denominator Weighted average shares outstanding used in computing net loss per share Basic 18,323,542 16,637,606 18,250,775 16,907,482 Effect of dilutive stock options, warrants, and stock grants — — — — Diluted 18,323,542 16,637,606 18,250,775 16,907,482 Net loss per share Basic $ (0.50 ) $ (0.17 ) $ (1.10 ) $ (0.79 ) Diluted $ (0.50 ) $ (0.17 ) $ (1.10 ) $ (0.79 ) The number of common shares potentially issuable upon the exercise of certain options and the vesting of certain restricted stock units that were excluded from the diluted loss per common share calculation are reflected in the table below. Three Months Ended Nine Months Ended Weighted average number of shares for the periods ended 2024 2023 2024 2023 Options 2,645 7,433 8,850 17,736 Unvested restricted stock unit awards 73,938 3,739 138,074 23,341 Total 76,583 11,172 146,924 41,077

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2024
Commitments And Contingencies [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 12 – COMMITMENTS AND CONTINGENCIES Litigation From time to time, the Company may become involved in legal proceedings or be subject to claims arising in the ordinary course of our business. We are currently not a party to any material legal or administrative proceedings, and we are not aware of any pending or threatened material legal or administrative proceedings against us. Commitments From time to time, the Company enters into arrangements with partners to acquire minimum amounts of media, data or messaging capabilities. As of September 30, 2024, the Company had commitments for future minimum payments of $16.7 million that will be reflected in cost of revenues during the years from 2024 through 2028. Minimum payments are due in the remainder of 2024 and fiscal 2025, 2026, 2027 and 2028 in the amounts of $1.8 million, $8.8 million, $3.6 million, $2.4 million and $0.1 million, respectively.

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2024
Income Taxes [Abstract]
INCOME TAXES	NOTE 13 – INCOME TAXES The Company reported a benefit from income taxes of $817 and $1,561 for the three and nine months ended September 30, 2024, representing an effective tax rate of 8.2% and 7.2%. The effective tax rate for the three and nine months ended September 30, 2024 reflects the impact of certain permanent items, projected increases in our valuation allowance during the year and discrete items for the quarter related to stock based compensation. There was no As discussed in our annual report on Form 10-K for the year ended December 31, 2023, we had net operating loss carry-forwards for federal income tax purposes of approximately $16.7 million as of December 31, 2023.

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2024
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 14 – SUBSEQUENT EVENTS Subsequent to September 30, 2024, we made a voluntary principal payment of $2 million on our Term Loan balance.

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023
Pay vs Performance Disclosure
Net Income (Loss)	$ (9,124)	$ (4,008)	$ (6,900)	$ (2,865)	$ (4,161)	$ (6,398)	$ (20,032)	$ (13,424)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Sep. 30, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Nature of Business and Basis _2

Nature of Business and Basis of Presentation (Tables)	9 Months Ended
	Sep. 30, 2024
Nature of Business and Basis of Presentation [Abstract]
Schedule of Pro-Forma Consolidated Statement of Operations	The following presents the pro forma consolidated statement of operations as if Medicx Health had been included in the consolidated results of the Company for the three and nine months ended September 30, 2023: Three Months Nine Months Pro-forma consolidated statement of operations September 30, Revenue $ 23,852 $ 67,291 Net loss (3,484 ) (18,141 )

Long-Term Debt (Tables)

Long-Term Debt (Tables)	9 Months Ended
	Sep. 30, 2024
Long-Term Debt [Abstract]
Schedule of Long-term Debt, Net	Long-term debt, net comprised the following at September 30, 2024 and December 31, 2023: September 30, December 31, Term Loan, due in 2027 $ 36,790 $ 38,290 Less: current portion (2,000 ) (2,000 ) Less: unamortized issuance costs (1,512 ) (2,059 ) Long-term debt, net $ 33,278 $ 34,231
Schedule of Repayments Due to Term Loan	Repayments of the Term Loan due under the terms of the financing agreement, including an estimate of the amount associated with the Excess Cash Flow calculation discussed above, for the remainder of the current and in each of the next three fiscal years are as follows: As of September 30, 2024 2024 (remainder) $ 500 2025 2,000 2026 2,000 2027 32,290 $ 36,790

Leases (Tables)

Leases (Tables)	9 Months Ended
	Sep. 30, 2024
Leases [Abstract]
Schedule of Lease Cost	For the three and nine months ended September 30, 2024 and 2023, the Company’s lease costs consist of the following components, each of which is included in operating expenses within the Company’s condensed consolidated statements of operations: Three months ended Nine Months Ended 2024 2023 2024 2023 Operating lease cost $ 62 $ 11 $ 186 $ 61 Short-term lease cost 1 19 2 27 Total lease cost $ 63 $ 30 $ 188 $ 88
Schedule of Future Minimum Lease Payments	The table below presents the future minimum lease payments to be made under operating leases in each of the remainder of the current and next four fiscal years and thereafter: As of September 30, 2024 2024 (remainder) $ 67 2025 188 2026 114 2027 67 2028 46 Thereafter — Total 482 Less: discount 45 Total lease liabilities $ 437

Revenues (Tables)

Revenues (Tables)	9 Months Ended
	Sep. 30, 2024
Revenues [Abstract]
Schedule of Deferred Revenue	The following is a summary of activity for the deferred revenue account for the nine months ended September 30: 2024 2023 Balance January 1 $ 172 $ 164 Revenue recognized (3,228 ) (2,444 ) Amount collected 3,961 3,015 Balance March 31 $ 905 $ 735 Revenue recognized (1,853 ) (3,171 ) Amount collected 2,002 2,887 Balance June 30 $ 1,054 $ 451 Revenue recognized (2,721 ) (3,043 ) Amount collected 2,453 2,780 Balance September 30 $ 786 $ 188
Schedule of Revenue Recognition	A break down is set forth in the table below. Three Months Ended Nine Months Ended 2024 2023 2024 2023 Revenue recognized over time $ 20,441 $ 14,815 $ 54,189 $ 40,421 Revenue recognized at a point in time 868 1,516 5,622 2,732 Total Revenue $ 21,309 $ 16,331 $ 59,811 $ 43,153
Schedule of the Allowance for Credit Losses	The following is a summary of changes in the allowance for credit losses for the nine months ended September 30,: 2024 2023 Balance at January 1, $ 239 $ 352 Bad debt expense 132 128 Write-offs — — Balance at March 31, $ 371 $ 480 Bad debt expense — 111 Write-offs — — Balance at June 30, $ 371 $ 591 Bad debt expense (1 ) 239 Write-offs 31 9 Balance at September 30, $ 339 $ 821

Loss Per Share (Tables)

Loss Per Share (Tables)	9 Months Ended
	Sep. 30, 2024
Loss Per Share [Abstract]
Schedule of Basic and Diluted Net Loss Per Share	The following table sets forth the computation of basic and diluted net loss per share. Three Months Ended Nine Months Ended 2024 2023 2024 2023 Numerator Net loss $ (9,124 ) $ (2,865 ) $ (20,032 ) $ (13,424 ) Denominator Weighted average shares outstanding used in computing net loss per share Basic 18,323,542 16,637,606 18,250,775 16,907,482 Effect of dilutive stock options, warrants, and stock grants — — — — Diluted 18,323,542 16,637,606 18,250,775 16,907,482 Net loss per share Basic $ (0.50 ) $ (0.17 ) $ (1.10 ) $ (0.79 ) Diluted $ (0.50 ) $ (0.17 ) $ (1.10 ) $ (0.79 )
Schedule of Vesting of Certain Restricted Stock Units	The number of common shares potentially issuable upon the exercise of certain options and the vesting of certain restricted stock units that were excluded from the diluted loss per common share calculation are reflected in the table below. Three Months Ended Nine Months Ended Weighted average number of shares for the periods ended 2024 2023 2024 2023 Options 2,645 7,433 8,850 17,736 Unvested restricted stock unit awards 73,938 3,739 138,074 23,341 Total 76,583 11,172 146,924 41,077

Nature of Business and Basis _3

Nature of Business and Basis of Presentation (Details) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2024 USD ($)	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)	Oct. 24, 2023
Nature of Business and Basis of Presentation [Line Items]
Number of US providers		2,000,000
Revenue		$ 67,291	$ 23,852
Healthy Offers, Inc [Member]
Nature of Business and Basis of Presentation [Line Items]
Acquire outstanding percentage				100%
Business Acquisition [Member]
Nature of Business and Basis of Presentation [Line Items]
Revenue	$ 1,088	$ 4,169

Nature of Business and Basis _4

Nature of Business and Basis of Presentation (Details) - Schedule of Pro-Forma Consolidated Statement of Operations - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Schedule of Pro-Forma Consolidated Statement of Operations [Abstract]
Revenue	$ 67,291	$ 23,852
Net loss	$ (18,141)	$ (3,484)

Cash, Cash Equivalents and Sh_2

Cash, Cash Equivalents and Short-Term Investments (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Cash, Cash Equivalents and Short-Term Investments [Abstract]
Money market funds at cost	$ 8,200,000	$ 0

Capitalized Software Costs (Det

Capitalized Software Costs (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Capitalized Software Costs [Abstract]
Amortization of software expense	$ 91	$ 48	$ 233	$ 143
Construction in process	$ 217		$ 217		$ 696

Goodwill (Details)

Goodwill (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Goodwill [Abstract]
Goodwill	$ 70,869		$ 70,869		$ 78,357
Goodwill impairment	$ 7,489		$ 7,489

Long-Term Debt (Details)

Long-Term Debt (Details) - USD ($)	3 Months Ended	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Oct. 11, 2023
Long-Term Debt [Line Items]
Term loan	$ 36,790,000	$ 36,790,000		$ 38,290,000
Amortization of debt issuance cost	$ 182,000	$ 547,000
Leverage ratio description		In addition, the Company is required to make a mandatory prepayment on March 31, of each year, commencing with 2025, equivalent to Excess Cash Flow multiplied by a percentage factor of 25%, if the leverage ratio is 3.60 to 1.00 or less, 50% if the leverage ratio is greater than 3.60 to 1 or less than or equal; to 4.10 to 1.00 and 75%, if the leverage ratio is greater than 4.10 to 1.00.
Term Loan [Member]
Long-Term Debt [Line Items]
Term loan					$ 40,000,000
Term loan bears interest percentage	14%	14%
Effective rate	16.10%	16.10%		1.25%
Original principal amount				$ 500

Long-Term Debt (Details) - Sche

Long-Term Debt (Details) - Schedule of Long-term Debt, Net - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Schedule of Long-term Debt, Net [Abstract]
Term Loan, due in 2027	$ 36,790	$ 38,290
Less: current portion	(2,000)	(2,000)
Less: unamortized issuance costs	(1,512)	(2,059)
Long-term debt, net	$ 33,278	$ 34,231

Long-Term Debt (Details) - Sc_2

Long-Term Debt (Details) - Schedule of Repayments Due to Term Loan - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Schedule of Repayments Due to Term Loan [Abstract]
2024 (remainder)	$ 500
2025	2,000
2026	2,000
2027	32,290
Total	$ 36,790	$ 38,290

Leases (Details)

Leases (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Leases [Abstract]
Weighted average remaining lease term	2 years 8 months 12 days
Weighted average discount rate	6.96%
Cash paid for measurement of lease liabilities	$ 168	$ 53
Operating lease payment payments on lease obligation	193	60
Amortization right of use assets	$ 175	$ 61

Leases (Details) - Schedule of

Leases (Details) - Schedule of Lease Cost - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Schedule of Lease Cost [Abstract]
Operating lease cost	$ 62	$ 11	$ 186	$ 61
Short-term lease cost	1	19	2	27
Total lease cost	$ 63	$ 30	$ 188	$ 88

Leases (Details) - Schedule o_2

Leases (Details) - Schedule of Future Minimum Lease Payments $ in Thousands	Sep. 30, 2024 USD ($)
Schedule of Future Minimum Lease Payments [Abstract]
2024 (remainder)	$ 67
2025	188
2026	114
2027	67
2028	46
Thereafter
Total	482
Less: discount	45
Total lease liabilities	$ 437

Stockholders' Equity (Details)

Stockholders' Equity (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended						6 Months Ended		9 Months Ended
	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2024	Jun. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Stockholders Equity [Line Items]
Preferred stock, shares authorized	10,000,000								10,000,000		10,000,000
Preferred stock, par value (in Dollars per share)	$ 0.001								$ 0.001		$ 0.001
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, shares authorized	166,666,667								166,666,667		166,666,667
Common stock, par value (in Dollars per share)	$ 0.001								$ 0.001		$ 0.001
Treasury common stock outstanding	1,741,397								1,741,397		1,741,397
Common stock were issued	20,069,432								20,069,432		19,899,679
Restricted stock withholding shares									52,092
Restricted stock withholding value (in Dollars)									$ 585,571
Proceeds of common stock received amount (in Dollars)					$ 105	$ 41
Share repurchase program authorized amount (in Dollars)						$ 15,000
Repurchased value (in Dollars)					$ 7,522
Treasury Stock [Member]
Stockholders Equity [Line Items]
Repurchased value (in Dollars)										$ 7,522
Common Stock [Member]
Stockholders Equity [Line Items]
Common stock, shares authorized	166,666,667								166,666,667
Common stock, par value (in Dollars per share)	$ 0.001								$ 0.001
Common stock shares outstanding	18,328,035								18,328,035		18,158,282
Treasury common stock outstanding	1,741,397								1,741,397		1,741,397
Common stock were issued
Shares issued of common stock					10,000	9,668
Shares of common stock	7,525	140,028	22,200	10,149	35,260	33,272	140,028		7,525
Restricted stock withholding shares									28,157
Restricted stock withholding value (in Dollars)										$ 121
Proceeds of common stock received amount (in Dollars)
Repurchased value (in Dollars)
Common Stock [Member] | 2013 Incentive Plan [Member]
Stockholders Equity [Line Items]
Shares issued of common stock						9,668		10,000		0
Shares of common stock						33,272		35,260		10,149
Proceeds of common stock received amount (in Dollars)						$ 40		$ 105		$ 0
Treasury Stocks [Member]
Stockholders Equity [Line Items]
Shares issued of common stock
Shares of common stock
Proceeds of common stock received amount (in Dollars)
Repurchased shares					(526,999)
Repurchased value (in Dollars)					$ 1
Treasury Stocks [Member] | Treasury Stock [Member]
Stockholders Equity [Line Items]
Repurchased shares				0					526,999

Stock Based Compensation (Detai

Stock Based Compensation (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2024	Sep. 30, 2023	Jun. 05, 2024
Stock Based Compensation [Line Items]
Number of shares of common stock available for awards (in Shares)				4,450,000
Compensation expense		$ 591	$ 541
Remaining expense	$ 4,115	$ 4,115
Weighted average period		1 year 6 months 25 days
Total intrinsic value of outstanding options	8	$ 8
Stock expense		16
Restricted stock units expense		$ 16
Vesting period		1 year
Stock Options [Member]
Stock Based Compensation [Line Items]
Compensation expense		$ 3,494	4,720
Stock expense	8
Restricted Stock Units (RSUs) [Member]
Stock Based Compensation [Line Items]
Compensation expense		5,036	$ 6,370
Expenses related to restricted stock	6,793	$ 6,793
Weighted average period		1 year 7 months 6 days
Restricted stock units expense	$ 8
2021 Equity Incentive Plan [Member]
Stock Based Compensation [Line Items]
Number of shares of common stock available for awards (in Shares)				1,950,000

Revenues (Details)

Revenues (Details) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Jan. 01, 2024	Dec. 31, 2023	Jan. 01, 2023
Revenues [Line Items]
Contract balance	$ 23,191							$ 2,021
Deferred revenue	786	$ 1,054	$ 905	$ 188	$ 451	$ 735	$ 172	172	$ 164
Recognized revenue	(2,721)	$ (1,853)	$ (3,228)	$ (3,043)	$ (3,171)	$ (2,444)
Eversana and LifeMD [Member]
Revenues [Line Items]
Recognized revenue	200
Unbilled Revenues [Member]
Revenues [Line Items]
Unbilled amounts	$ 6,002							$ 3,288

Revenues (Details) - Schedule o

Revenues (Details) - Schedule of Deferred Revenue - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Jan. 01, 2024	Dec. 31, 2023	Jan. 01, 2023
Revenue From Contract With Customer Abstract
Contract with Customer, Liability, Current	$ 786	$ 1,054	$ 905	$ 188	$ 451	$ 735	$ 172	$ 172	$ 164
Contract with Customer, Liability, Revenue Recognized	(2,721)	(1,853)	(3,228)	(3,043)	(3,171)	(2,444)
ContractWithCustomerLiabilityAmountCollected	$ 2,453	$ 2,002	$ 3,961	$ 2,780	$ 2,887	$ 3,015

Revenues (Details) - Schedule_2

Revenues (Details) - Schedule of Revenue Recognition - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Schedule of Revenue Recognition [Line Items]
Total Revenue	$ 21,309	$ 16,331	$ 59,811	$ 43,153
Revenue recognized over time [Member]
Schedule of Revenue Recognition [Line Items]
Total Revenue	20,441	14,815	54,189	40,421
Revenue recognized at a point in time [Member]
Schedule of Revenue Recognition [Line Items]
Total Revenue	$ 868	$ 1,516	$ 5,622	$ 2,732

Revenues (Details) - Schedule_3

Revenues (Details) - Schedule of the Allowance for Credit Losses - USD ($) $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Revenue From Contract With Customer Abstract
Accounts Receivable, Allowance for Credit Loss, Current	$ 339	$ 371	$ 371	$ 821	$ 591	$ 480	$ 339	$ 821	$ 239	$ 352
Accounts Receivable, Credit Loss Expense (Reversal)	(1)		132	239	111	128	$ 131	$ 478
Accounts Receivable, Allowance for Credit Loss, Writeoff	$ 31			$ 9

Loss Per Share (Details) - Sche

Loss Per Share (Details) - Schedule of Basic and Diluted Net Loss Per Share - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023
Numerator
Net loss (in Dollars)	$ (9,124)	$ (4,008)	$ (6,900)	$ (2,865)	$ (4,161)	$ (6,398)	$ (20,032)	$ (13,424)
Weighted average shares outstanding used in computing net loss per share
Basic	18,323,542			16,637,606			18,250,775	16,907,482
Effect of dilutive stock options, warrants, and stock grants
Diluted	18,323,542			16,637,606			18,250,775	16,907,482
Net loss per share
Basic (in Dollars per share)	$ (0.5)			$ (0.17)			$ (1.1)	$ (0.79)
Diluted (in Dollars per share)	$ (0.5)			$ (0.17)			$ (1.1)	$ (0.79)

Loss Per Share (Details) - Sc_2

Loss Per Share (Details) - Schedule of Vesting of Certain Restricted Stock Units - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Schedule of Vesting of Certain Restricted Stock Units [Line Items]
Total			146,924	41,077
Restricted Stock Units (RSUs) [Member]
Schedule of Vesting of Certain Restricted Stock Units [Line Items]
Total	76,583	11,172
Options [Member]
Schedule of Vesting of Certain Restricted Stock Units [Line Items]
Total			8,850	17,736
Options [Member] | Restricted Stock Units (RSUs) [Member]
Schedule of Vesting of Certain Restricted Stock Units [Line Items]
Total	2,645	7,433
Unvested Restricted Stock Unit Awards [Member]
Schedule of Vesting of Certain Restricted Stock Units [Line Items]
Total			138,074	23,341
Unvested Restricted Stock Unit Awards [Member] | Restricted Stock Units (RSUs) [Member]
Schedule of Vesting of Certain Restricted Stock Units [Line Items]
Total	73,938	3,739

Commitments and Contingencies (

Commitments and Contingencies (Details) $ in Millions	Sep. 30, 2024 USD ($)
Commitments And Contingencies [Abstract]
Total future minimum payment amount	$ 16.7
Minimum payment due in the remainder	1.8
Minimum payment due one	8.8
Minimum payment due two	3.6
Minimum payment due three	2.4
Minimum payment due four	$ 0.1

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Income Taxes [Abstract]
Benefit from income taxes	$ (817)		$ (1,561)
Percentage of effective tax rate	8.20%		7.20%
Provision for or benefit from taxes
Net operating loss carryforwards					$ 16,700

Subsequent Events (Details)

Subsequent Events (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Subsequent Events [Abstract]
Long term debt	$ 2,000	$ 2,000